Bristol Myers Buys Nvidia's Latest AI Computing System for Drug Research

Bristol Myers Squibb (BMY) announced on Monday that it will purchase the latest computing system from Nvidia (NVDA) to support its use of artificial intelligence in drug discovery and development operations. The drugmaker will be the first life sciences company to buy an Nvidia DGX SuperPOD based on its Vera Rubin systems.

The Product

Nvidia's DGX SuperPOD is a supercomputer designed for AI applications, based on the latest Vera Rubin architecture unveiled earlier this year as the successor to Nvidia's current generation of AI computing systems. The system offers massive computing power to train complex AI models quickly and efficiently.

Pricing and Availability

Neither company disclosed the value or terms of the deal. Delivery of the system to Bristol Myers is expected later this year.

Competition

Nvidia competes with companies like AMD and Intel in the AI computing market, but maintains a dominant market share thanks to its integrated hardware and software platform. In the life sciences sector, companies like Pfizer and Roche use similar systems from competitors, but the Bristol Myers deal gives Nvidia a strong foothold in this segment.

Potential Impact on the Companies

For Bristol Myers, the new system is expected to accelerate drug discovery and reduce costs, potentially strengthening its drug pipeline. For Nvidia, the deal represents expansion into the fast-growing life sciences market and could pave the way for similar deals with other pharmaceutical companies.